NCT02939326

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Bonti, Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).

Detailed description

This study of EB-001 to measure safety and efficacy in GL. Single doses of EB- 001 administered through IM injection into procerus at midline and the medial and lateral corrugators will be assessed in healthy subjects with glabellar frown lines.

Conditions

• Glabellar Frown Lines (GL)

Interventions

Type	Name	Description
DRUG	EB-001 injection
DRUG	Placebo injection

Timeline

• Start date: 2016-12-01
• Primary completion: 2017-07-12
• Completion: 2017-07-12
• First posted: 2016-10-20
• Last updated: 2019-02-15
• Results posted: 2019-02-15

Locations

2 sites across 1 country: United States